Integrating treatment cost reduction strategies and biomarker research to reduce costs and personalize expensive treatments: an example of a self-funding trial in non-small cell lung cancer

Autor: Alessandra I. G. Buma, Berber Piet, Rob ter Heine, Michel M. van den Heuvel, Paul Brinkman, Daan van den Broek, Sjaak Burgers, Francesco Ciompi, Simona M. Cristescu, Bram van Ginneken, Katrien Grünberg, Lizza Hendriks, Jeroen Hiltermann, Firdaus Mohamed Housein, Alwin Huitema, Jakko van Inge, Colin Jacobs, Hans Koenen, Marjolijn Ligtenberg, Anke H. Maitland-van der Zee, Vincent van der Noort, Mathias Prokop, Valesca Rètel, Heinrich Roder, Huub van Rossum, Ruben Smeets, Thomas Würdinger

Publikováno v: Frontiers in Pharmacology, Vol 14 (2023)

Personalization of treatment offers the opportunity to treat patients more effectively based on their dominant disease-specific features. The increasing number and types of treatment, and the high costs associated with these treatments, however, dema

Externí odkaz: https://doaj.org/article/625220bc2e1044659b79873cb9c7aed9

P676: UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA

Autor: Erica Brivio, Edoardo Pennesi, Marieke Willemse, Yilin Jiang, Vincent van der Velden, Berna Beverloo, Chad Hudson, Luke Kuttschreuter, Inge van der Sluis, Benoît Brethon, Francisco Bautista, Michael J. Burke, Nyla Heerema, Andrew Bukowinski, Stacy Cooper, Jessica Pollard, Ramamoorthy Nagasubramani, Michele Redell, Jean-Pierre Bourquin, Ray Pais, Jamie Frediani, Sandeep Batra, Nicoletta Bertorello, Jessica Boklan, Albert Kheradpour, Wade Kyono, Karey Kowalski, Benjamin Mizukawa, Donna Lancaster, Laura Murillo-Sanjuán, Julie Krystal, Yves Bertrand, Alwin Huitema, Harm van Tinteren, Franco Locatelli, Michael Roth, Nobuko Hijiya, Michel Zwaan

Publikováno v: HemaSphere, Vol 7, p e506783a (2023)

Externí odkaz: https://doaj.org/article/3cf4638bbdd34168801ad993f868db27

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?

Autor: Alaa Embaby, Lisanne van Merendonk, Neeltje Steeghs, Jos Beijnen, Alwin Huitema

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

Beta-blockers are currently studied to improve therapeutic options for patients with angiosarcoma. However, most of these patients have no cardiovascular co-morbidity and it is therefore crucial to discuss the most optimal pharmacological properties

Externí odkaz: https://doaj.org/article/e3f8577820e144b5a99f96a9d9b330bb

Clinical development of WEE1 inhibitors in gynecological cancers:A systematic review

Autor: Tim Schutte, Alaa Embaby, Neeltje Steeghs, Stevie van der Mierden, Willemien van Driel, Martin Rijlaarsdam, Alwin Huitema, Frans Opdam

Publikováno v: Schutte, T, Embaby, A, Steeghs, N, van der Mierden, S, van Driel, W, Rijlaarsdam, M, Huitema, A & Opdam, F 2023, ' Clinical development of WEE1 inhibitors in gynecological cancers : A systematic review ', Cancer Treatment Reviews, vol. 115, 102531 . https://doi.org/10.1016/j.ctrv.2023.102531

Introduction: The anti-tumor activity of WEE1 inhibitors (WEE1i) in gynecological malignancies has recently been demonstrated in clinical trials and its rationale is based on biological/molecular features of gynecological cancers. With this systemati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5cdcbd88b8c866daf5e90d362d7eb25
https://research.vumc.nl/en/publications/b5097863-18b7-404c-8157-c655859b03f8

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

Autor: Christoph Driessen, Marianne Kraus, Markus Joerger, Hilde Rosing, Jürgen Bader, Felicitas Hitz, Catherine Berset, Alexandros Xyrafas, Hanne Hawle, Gregoire Berthod, Hermann S. Overkleeft, Christiana Sessa, Alwin Huitema, Thomas Pabst, Roger von Moos, Dagmar Hess, Ulrich J.M. Mey

Publikováno v: Haematologica, Vol 101, Iss 3 (2016)

Downregulation of the unfolded protein response mediates proteasome inhibitor resistance in multiple myeloma. The Human Immunodeficieny Virus protease inhibitor nelfinavir activates the unfolded protein response in vitro. We determined dose-limiting

Externí odkaz: https://doaj.org/article/bc92048d9b7b4dcea541e2cf1878d82c